Development asset linked to Peking University Biologics in public FDA and regional records.
pharma · Clear Cell Renal Cell Carcinoma · Cushing s Syndrome
Peking University Biologics
Peking University Third Hospital
Peking University Biologics drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
仙霞路, 319号, 上海市, 长宁区, CN HQ
2018 Founded
8 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 仙霞路, 319号, 上海市, 长宁区, CN
- Founded
- 2018
- Employees
- 8
- Programs
- 15
- Drugs
- 25
- Patents
- 0
Peking University Biologics pipeline
Portfolio lens on 25 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Peking University Biologics drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Peking University Biologics's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Surfactant agent.
- Mechanism
- Surfactant agent
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
dexmedetomidine
Nervous system (N05)Nervous system (N05) compound in Peking University Biologics's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
glofitamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Peking University Biologics's portfolio. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
lutropin alfa
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in Peking University Biologics's portfolio. Molecular target: Lutropin-choriogonadotropic hormone receptor.
- Target
- Lutropin-choriogonadotropic hormone receptor
- Mechanism
- Luteinizing hormone/Choriogonadotropin receptor agonist
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
roxadustat
Blood and blood forming organs (B03)Blood and blood forming organs (B03) compound in Peking University Biologics's portfolio. Molecular target: Hypoxia-inducible factor prolyl hydroxylase.
- Target
- Hypoxia-inducible factor prolyl hydroxylase
- Mechanism
- Hypoxia-inducible factor prolyl hydroxylase inhibitor
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
Development asset linked to Peking University Biologics in public FDA and regional records.
-
ticagrelor
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 negative allosteric modulator
-
Development asset linked to Peking University Biologics in public FDA and regional records.